Ongoing health technology assessments related to eHealth by NICE

30

Apr 2021

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

As of April 26, 2021, three MTGs related to eHealth technology are in development with the scheduled publication date:

cognitive behavioral therapy for insomnia (CBT‑I);

  • KardiaMobile for the ambulatory detection of atrial fibrillation - a portable single-lead electrocardiogram (ECG) recorder. The monitor works with a compatible mobile device (such as a smartphone or tablet) running the Kardia app, which analyses the ECG recording and sends it to a healthcare professional for interpretation.

The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

As of April 26, 2021, one DG concerned eHealth technology are in development with the scheduled publication date:

MedTech Innovation Briefing (MIB) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.

As of April 26, 2021, nine MIBs concerned eHealth technology are in development with the scheduled publication date:

  • Personal KinetiGraph – a system that consists of a wrist-worn movement recording device, proprietary algorithms, and a data-driven report (known as the PKG), and provides objective ambulatory continuous assessment of motor complications associated with movement disorders;
  • AI Chest Imaging – no further information is available;
  • AI Bone Health - no further information is available;
  • Syne-COV COVID prediction algorithm – an AI algorithm developed by the UK company Sensyne Health in collaboration with Chelsea & Westminster Hospitals NHS Foundation Trust. It generates a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation, or admission to intensive care;
  • MyoVista Wavelet ECG Cardiac Testing Device - a new resting 12-lead electrocardiograph that uses continuous wavelet transform (CWT) signal processing to detect cardiac relaxation abnormalities associated with left ventricular diastolic dysfunction (AI-based technology);
  • Acumen IQ sensor for predicting hypotension risk - connects to any existing radial arterial line and uses the proprietary algorithm, developed with machine learning to detect the likelihood of hypotensive trending of a patient mean arterial pressure;
  • Oncolaxy for remote follow up of people living with cancer - an advanced e-PRO (electronic Patient Reported Outcomes) system, allowing for home surveillance with qualified alerts by a certified medical algorithm;
  • RapidAI for analyzing CT/MRI brain scans – AI-based platform to create high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes;
  • Imbio Lung Texture Analysis for measurement of interstitial lung disease (ILD) - applies advanced computer vision to transform a standard chest CT into a detailed map of the lung textures that are key to identifying ILD's and other fibrotic conditions.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

12

May 2021

The Agency for Health Technology Assessment of Andalusia Autonomous Community in Spain (AETSA) systematically evaluates healthcare technologies and provides decision-makers with critically review information about their efficacy, safety, and effectiveness. Currently, the AETSA is working on assessments of laser-induced heat therapy in epilepsy surgery, stereotactic radiation therapy for the treatment of refractory ventricular tachycardia, implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring, and other topics.

Read more

11

May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more

10

May 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 6462 of April 21, 2021, Tuscany Regional Healthcare has published assessments of six medical devices of various therapeutic areas, including devices for the treatment of vaginal prolapse, cardiovascular conditions, an implant for vocal cord rehabilitation, and a cerebral embolic protective device.

Read more

06

May 2021

The Treatment Council (Behandlingsråd) is a new model for assessing treatment methods and health technologies, expected to become fully operational during 2021. The first meeting of the Treatment Council is planned to be conducted in May 2021. On April 15, 2021, the method and process frameworks of the Treatment Council (Behandlingsråd) were sent for consultation to the parties who have previously submitted consultation responses regarding these documents.

Read more

04

May 2021

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

Read more